Response to the Letter of Fagotti Et Al. Regarding the Manuscript: "Pattern of and Reason for Postoperative Residual Disease in Patients with Advanced Ovarian Cancer Following Upfront Radical Debulking Surgery"
Overview
Overview
Authors
Affiliations
Affiliations
Soon will be listed here.
Citing Articles
Ghisoni E, Katsaros D, Maggiorotto F, Aglietta M, Vaira M, De Simone M J Ovarian Res. 2018; 11(1):42.
PMID: 29843747 PMC: 5975698. DOI: 10.1186/s13048-018-0415-y.
References
1.
Harter P, Muallem Z, Buhrmann C, Lorenz D, Kaub C, Hils R
. Impact of a structured quality management program on surgical outcome in primary advanced ovarian cancer. Gynecol Oncol. 2011; 121(3):615-9.
DOI: 10.1016/j.ygyno.2011.02.014.
View
2.
Ataseven B, du Bois A, Harter P, Prader S, Grimm C, Kurzeder C
. Impact of Abdominal Wall Metastases on Prognosis in Epithelial Ovarian Cancer. Int J Gynecol Cancer. 2016; 26(9):1594-1600.
DOI: 10.1097/IGC.0000000000000826.
View
3.
Heitz F, Ognjenovic D, Harter P, Kommoss S, Ewald-Riegler N, Haberstroh M
. Abdominal wall metastases in patients with ovarian cancer after laparoscopic surgery: incidence, risk factors, and complications. Int J Gynecol Cancer. 2010; 20(1):41-6.
DOI: 10.1111/IGC.0b013e3181c443ba.
View
4.
Fagotti A, Ferrandina G, Vizzielli G, Fanfani F, Gallotta V, Chiantera V
. Phase III randomised clinical trial comparing primary surgery versus neoadjuvant chemotherapy in advanced epithelial ovarian cancer with high tumour load (SCORPION trial): Final analysis of peri-operative outcome. Eur J Cancer. 2016; 59:22-33.
DOI: 10.1016/j.ejca.2016.01.017.
View
5.
Vergote I, Trope C, Amant F, Kristensen G, Ehlen T, Johnson N
. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N Engl J Med. 2010; 363(10):943-53.
DOI: 10.1056/NEJMoa0908806.
View